Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Selegiline HCl, 10 mg per day has been reported to improve attention and episodic memory in Parkinson's disease and early Alzheimer's disease. Selegiline also improves motor reaction times in Parkinson's and subjective feelings of increased vitality, euphoria and energy. At doses of between 10 and 40 mg a day it has also been shown to improve depression particularly when psychomotor retardation is prominent and anxiety minimal.
 ...
PMID:Selegiline hydrochloride and cognition. 180 44

Bit-mapped multicomponent CNV complex and reaction time (RT) were recorded and measured in 24 presenile patients with initial symptoms of very mild to moderately severe primary mental deterioration without depression, and in 10 age-matched controls. All patients underwent CT and MRI examinations, EEG spectral analysis and a battery of psychometric test. Significant group differences were obtained for measures of some post-S1 ERP and CNV components, particularly of the post-S1 N1b, P300 and early and late pre-S2 CNV. P300 with increased latency, no significant CNV activity, very prolonged RTs, EEG slowing down and diffuse brain atrophy were observed in the majority of patients with probable presenile Alzheimer's dementia. These results suggest that CNV/RT and EEG activity changes similar to those observed in our patients may constitute a valuable clue for the study of brain dysfunction in the early stage of presenile idiopathic cognitive impairment.
 ...
PMID:Effect of physiological and pathological aging processes on topographic bit-mapped cognitive evoked potentials in presenile subjects. 180 55

We have studied visual evoked potentials (VEP) in four groups: healthy young and aged subjects and aged patients suffering from depression or Alzheimer's disease (AD). In the flash modality, peak IV delay in AD patients as compared to aged controls corresponded to lengthened III-IV interlatency (IL). When AD and depressed patients were compared, peak IV delay in the former did not reach significance. Normal aging resulted in delayed peaks II and III, without IL modification. In the pattern reversal modality, no difference was observed between AD patients and aged, healthy or depressed controls. Aging delayed peaks P50 to P180. The abnormality exhibited by AD patients was specific to this group. However, the lack of significant difference between AD and depressed groups argues against the ability of VEP to differentiate those conditions.
 ...
PMID:[Specificity of visual evoked potential alterations in Alzheimer's disease]. 180 1

The neuropsychological testing of 23 elderly depressed patients was compared to that of 23 healthy controls and 20 Alzheimer's disease (AD) patients. Depressed subjects were deficient relative to controls on most tasks, including naming and cued memory. There was a greater negative influence of age on the performance of depressed subjects (relative to controls) on some tasks. Despite their significant deficits, depressed patients were clearly distinguishable from AD patients. It is suggested that the combined effects of age and depression produce a pattern of deficits that is distinct from that of younger depressives, but less severe than that of Alzheimer's patients.
 ...
PMID:The neuropsychology of depression in the elderly: a comparative study of normal aging and Alzheimer's disease. 182 Dec 30

This study describes the psychophysiological results of a larger investigation of the clinical, morphological, psychometric and psychophysiological aspects of dementia of the Alzheimer type and depression in elderly patients. Healthy volunteers provided a further measure of control. It was found that widely used clinical rating scales delineated the 3 groups of subjects to a significant degree. The average frequency of the electroencephalogram (EEG), the P2-N2 peak-to-peak amplitude and P3 latency of the auditory evoked potential and a characteristic downward shift of the EEG power spectrum differed significantly between demented patients, depressive patients and normal controls. The higher total power in the EEG of the dementia group did not prove statistically significant, probably because of the small numbers. Other psychophysiological measures such as skin conductance level (SCL) and skin temperature (ST) did not reveal statistically significant differences between the groups. Thus, certain psychophysiological measurements may become valuable in the differential diagnosis of these disorders.
 ...
PMID:Dementia and depression in old age: psychophysiological aspects. 185 23

All incident cases of clinically diagnosed Alzheimer's disease were identified through the unique record linkage system of the Mayo Clinic. Thirty-nine (32%) of the sample of 122 had a psychiatric history that preceded the onset of CDAD by at least 3 years. Twenty-five percent of the study population had had an episode of delirium within 2 years of the onset of CDAD. Eighty-four percent of the cases had psychiatric symptoms in the course of CDAD that were documented in their medical records. Specific symptom patterns included agitation, combativeness, confusion and disorientation, depression, psychosis, and wandering. These symptoms occurred more frequently in clusters than singularly.
 ...
PMID:Psychiatric symptoms in cases of clinically diagnosed Alzheimer's disease. 185 24

This study is an investigation of the concordance among different sources of information on ratings of depression in patients with Alzheimer's disease (AD). Informants were 75 outpatients with diagnosed AD (22 with major depressive disorder), their caregivers, and geriatric clinicians. Clinicians rated each patient on the Hamilton Rating Scale for Depression on the basis of (a) the patient's report, (b) the caregiver's report, and (c) the clinician's evaluation. Overall, patients perceived themselves as less depressed than did caregivers or clinicians; for nondepressed patients, caregivers reported patients less depressed than clinicians reported; for depressed patients, no significant differences were obtained between caregiver or clinician. Certain items were more discrepant among informants and significantly differentiated depressed from nondepressed AD patients. Level of patient dementia did not affect ratings. These findings support the need for comprehensive, accurate assessment of depression in AD patients.
 ...
PMID:Assessment of depression in patients with Alzheimer's disease: concordance among informants. 186 97

The central functions of norepinephrine (NE) are a recent discovery: regulation of alertness and of the wakefulness-sleep cycle, maintenance of attention, memory and learning, cerebral plasticity and neuro-protection. The anatomical, histological, biochemical and physiological properties of the central noradrenergic system: extreme capacity for ramification and arborization; slow conduction, non-myelinized axons with extrasynaptic varicosities producing and releasing NE; frequency of co-transmission phenomena, and; neuromodulation with fiber effect responsible for improvement in the signal over background noise ratio and selection of significant stimuli form a true interface between the outside world and the central nervous system, notably for the neocortex in the context of the cognitive treatment of information. This central noradrenergic system is involved in the neurophysiology and the clinical features of cerebral aging (ideation-motor and cognitive function slowing down, loss of behavioral adjustment), neuro-degenerative disorders (SDAT, Parkinson's disease), certain aspects of depression and less obvious conditions (head injuries, sequelae of cerebrovascular accidents, sub-cortical dementia). The recent development of medications improving alertness (adrafinil, modafinil) with a pure central action and specifically noradrenergic, may contribute to an improvement in these multifactorial disorders.
 ...
PMID:[Noradrenaline and cerebral aging]. 186 52

A standardized, reliable means of assessing CT attenuation numbers in the centrum semiovale and surrounding grey matter was developed. This was applied to cranial CT scans of 60 normal controls (36 aged greater than 60 years), 25 elderly patients with major depression (14 of whom had the dementia syndrome of depression), and 10 patients with Alzheimer's disease (AD). Subjects received neuropsychological evaluation. Centrum semiovale (CSO) CT attenuation numbers decreased with increasing age for both white and grey matter. White matter attenuation values best discriminated elderly controls from the three patient groups. Both white and grey matter CSO attenuation values correlated with performance on a number of cognitive tasks.
 ...
PMID:Centrum semiovale white matter CT changes associated with normal ageing, Alzheimer's disease and late life depression with and without reversible dementia. 187 37

Factors affecting survival of 178 patients diagnosed using NINCDS/ADRDA criteria for Alzheimer's disease were studied. All patients were drawn from the Camberwell Health Authority Area and so were a representative sample of subjects from a clinical old age psychiatry service. The mortality rate of the sample was 3.5 times that expected after adjustment for age. Younger subjects had a higher standardized mortality ratio than older subjects. The cumulative three-year mortality of the sample was 47%. Factors shown to be associated with a reduced survival included: increasing age, longer duration of illness, male sex, presence of physical illness, poor cognitive function, observed depression and absence of misidentification syndromes. Apraxia was a stronger predictor of early death than aphasia or dysmnesia.
 ...
PMID:Factors affecting survival in Alzheimer's disease. 187 41


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>